Eli Lilly (LLY)
1,417.54
+43.84 (3.19%)
NYSE · Last Trade: Nov 1st, 12:10 PM EST
News & Press Releases
Eli Lilly’s First Full Medicare Quarter: Is Volume Still Outrunning Price Cuts?marketbeat.com
Eli Lilly posted 39% YOY revenue growth in Q3 2026 on strong Mounjaro and Zepbound sales, raising full-year guidance even as Medicare's GLP-1 Bridge program pressures drug pricing.
Via MarketBeat · November 1, 2026
Novo Nordisk Trades at 10 Times Earnings While Buying Back Billions in Stock. Is This the Bottom?fool.com
Novo Nordisk is shifting its business model, with 2026 likely to represent an inflection point.
Via The Motley Fool · November 1, 2026
What to expect from Jazz Pharmaceuticals’s (JAZZ) Q3 earnings
Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) will be reporting results this Monday after market hours. Here’s what to expect. Jazz Pharmaceuticals be...
Via StockStory · October 31, 2026
After Eli Lilly’s Explosive Earnings Report, Is It Too Late to Buy the Stock?fool.com
Eli Lilly stock is trading at a record high.
Via The Motley Fool · October 31, 2026
Eli Lilly (NYSE:LLY) Beats Q3 Estimates, Raises Guidance as Shares Jumpchartmill.com
Via Chartmill · October 29, 2026
Prediction: $100 per Month Invested in Eli Lilly (LLY) Stock Will Be Worth This Much by 2030fool.com
GLP-1 weight loss drugs are propelling profits for some drugmakers like Eli Lilly.
Via The Motley Fool · October 31, 2026
2 Stocks Billionaires Can't Stop Buyingfool.com
Should you buy these stocks, too?
Via The Motley Fool · October 31, 2026
What Eli Lilly and Company (LLY) Said on Its Q3 Earnings Callmarketbeat.com
Eli Lilly and Company (NYSE:LLY) raised its full-year outlook after reporting third-quarter revenue growth of 39% from the prior-year period, driven primarily by demand for its Mounjaro and Zepbound incretin medicines and continued growth across international markets.
Chair and CEO Dave Ricks said
Via MarketBeat · October 30, 2026
OmniAb (OABI) Q3 2026 Earnings Call Transcriptfool.com
Revenue jumped to $4M as xPloration expands and Lilly partnership unlocks $3B in milestones.
Via The Motley Fool · October 30, 2026
Eli Lilly Is Now Worth as Much as Warren Buffett's Berkshire Hathaway. Can the Rally Keep Going?fool.com
Eli Lilly's business is heavily driven by one product, while Berkshire Hathaway is a diversified conglomerate.
Via The Motley Fool · October 30, 2026
Can GLP-1s Fatten Your Portfolio? We Examine the VanEck Pharmaceutical ETF vs State Street SPDR Pharmaceuticals ETFfool.com
VanEck's concentrated 26-stock portfolio delivered stronger five-year returns and lower volatility, while State Street's 62-holding fund offers broader diversification and lower fees.
Via The Motley Fool · October 30, 2026
Novo Has Big Plans for 2030. Should You Buy the Stock Now?fool.com
The company’s comeback strategy looks sound.
Via The Motley Fool · October 29, 2026
Eli Lilly (LLY) Q3 2026 Earnings Call Transcriptfool.com
Revenue surged 39% on blockbuster obesity drug demand and strong international growth.
Via The Motley Fool · October 29, 2026
Eli Lilly Sells 53% More at Lower Prices: Rapid Earnings Reactionfool.com
Eli Lilly’s realized prices fell 15%, but a 53% jump in volume pushed revenue up 39% and lifted full-year guidance by $5.5 billion. Here’s why the math works, and what could break it.
Via The Motley Fool · October 29, 2026
S&P 500 Top Movers: Oct. 29, 2026 Gainers and Loserschartmill.com
Via Chartmill · October 29, 2026
S&P 500 Top Movers: Today's US Session Gainers and Loserschartmill.com
Via Chartmill · October 29, 2026
Eli Lilly (LLY) shares skyrocket, what you need to know
What happened? Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 8.1% in the morning session after the company reported third-quarter 2026 ...
Via StockStory · October 29, 2026
S&P 500 Gap Movers: October 29, 2026 Sessionchartmill.com
Via Chartmill · October 29, 2026
The $294 Billion Peptide Boom: Biotech Companies Positioned for the Next Wave of Growth
Breakthroughs in obesity, diabetes, oncology, and targeted therapies are driving fresh interest in peptide-based medicines and the companies developing the next generation of treatments.
By FN Media · Via GlobeNewswire · October 29, 2026
The $294 Billion Peptide Boom: Biotech Companies Positioned for the Next Wave of Growth
EQNX::TICKER_START (OTCQB:PNGAF),(CSE:BPC),(NYSE:NVO),(NYSE:HIMS),(NYSE:ENHA),(NYSE:LLY) EQNX::TICKER_END
Via FinancialNewsMedia · October 29, 2026
Eli Lilly Blows Past Sales Expectations And Hikes Outlook On Mounjaro, Zepbound Dominanceinvestors.com
Eli Lilly stock jumped early Thursday on a solid third-quarter report on the back of Mounjaro and Zepbound.
Via Investor's Business Daily · October 29, 2026
Eli Lilly (NYSE:LLY) reports upbeat Q3 2026, guides for strong full-year sales
Global pharmaceutical company Eli Lilly (NYSE:LLY) reported Q3 2026 results beating Wall Street’s revenue expectations, with revenue up 38.6% year on year to...
Via StockStory · October 29, 2026
Could Revolution Medicines Be a Millionaire-Maker Stock?fool.com
The path for Revolution Medicines to grow an initial investment of $25,000 into $1 million is a daunting one.
Via The Motley Fool · October 29, 2026
Eli Lilly's Next-Gen Obesity Drug Trounces Ozempic In Head-To-Head Testinvestors.com
Eli Lilly's next-generation weight-loss drug, retatrutide, trounced Novo's Ozempic in a head-to-head study.
Via Investor's Business Daily · October 28, 2026
Eli Lilly (LLY) reports earnings tomorrow: what to expect
Global pharmaceutical company Eli Lilly (NYSE:LLY) will be reporting earnings this Thursday before market hours. Here’s what you need to know. Eli Lilly beat...
Via StockStory · October 27, 2026